Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2012

01-12-2012 | Original Article

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

Authors: M. Provencio, C. Camps, M. Cobo, R. De las Peñas, B. Massuti, R. Blanco, V. Alberola, U. Jimenez, J. R. Delgado, F. Cardenal, M. Tarón, J. L. Ramírez, A. Sanchez, R. Rosell

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2012

Login to get access

Abstract

Purpose

New therapeutic approaches are being developed based on findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) can influence chemosensitivity. The identification of molecular markers, useful for therapeutic decisions in lung cancer, is thus crucial for disease management. The present study evaluated single-nucleotide polymorphisms (SNPs) in XRCC3, XPD and Aurora kinase A in NSCLC patients in order to assess whether these biomarkers were able to predict the outcomes of the patients.

Methods

The Spanish Lung Cancer Group prospectively assessed this clinical study. Eligible patients had histologically confirmed stage IV or IIIB (with malignant pleural effusion) NSCLC, which had not previously been treated with chemotherapy, and a World Health Organization performance status (PS) of 0–1. Patients received intravenous doses of vinorelbine 25 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1, every 21 days for a maximum of 6 cycles. Venous blood was collected from each, and genomic DNA was isolated. SNPs in XRCC3 T241M, XPD K751Q, XPD D312N, AURORA 91, AURORA 169 were assessed.

Results

The study included 180 patients. Median age was 62 years; 87 % were male; 34 % had PS 0; and 83 % had stage IV disease. The median number of cycles was 4. Time to progression was 5.1 months (95 % CI, 4.2–5.9). Overall median survival was 8.6 months (95 % CI, 7.1–10.1). There was no significant association between SNPs in XRCC3 T241M, XPD K751Q, XPD D312N, AURORA 91, AURORA 169 in outcome or toxicity.

Conclusions

Our findings indicate that SNPs in XRCC3, XPD or Aurora kinase A cannot predict outcomes in advanced NSCLC patients treated with platinum-based chemotherapy.
Literature
1.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551PubMedCrossRef
2.
Fossella F, Pereira JR, Von Pawel J, Pluzanska A, Gorbounova V et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024PubMedCrossRef
3.
Gebbia V, Galette D, Caruso M, Verderame F, Pezzella G et al (2008) Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 3:369–377CrossRef
4.
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58PubMedCrossRef
5.
van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D et al (2010) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89:160–166
6.
Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH et al (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells (2002). Cancer Res 62:4899–4902PubMed
7.
de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668–675PubMedCrossRef
8.
Aloyz R, Zy Xu, Bello V, Bergeron J, Han FY et al (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457–5462PubMed
9.
Spitz MR, Wu X, Wang Y, Wang LE, Shete S et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354–1357PubMed
10.
Gurubhagavatula S, Liu G, Park S, Zhou W, Su L et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594–2601PubMedCrossRef
11.
Gautschi O, Heigway J, Mack P, Purnell PR, Lara PN et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639–1648PubMedCrossRef
12.
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547–566PubMedCrossRef
13.
Mora-Bermudez F, Gerlich D, Ellenberg J (2007) Maximal chromosomes compaction occurs by axial shortening in anaphase and depends on aurora kinase. Nat Cell Biol 9:822–831PubMedCrossRef
14.
Soncini C, Carpinelli P, Gianelli L, Fancelli D, Vianello P et al (2006) PHA-680632 a novel aurora kinase inhibitor with potent antitumoural activity. Clin Cancer Res 12:4080–4089PubMedCrossRef
15.
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ et al (2007) AZD 1152, a selective inhibitor of aurora B kinase, inhibits human xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682–3688PubMedCrossRef
16.
Tong T, Zhong Y, Kong J, Dong L, Song Y et al (2004) Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10(7304):7310 Erratum in: Clin Cancer Res. 2005 Jun 15;11(12):4635
17.
Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB et al (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9:991–997PubMed
18.
Sakakura C, Hagiwara A, Yasuoka R, Funjita Y, Nakanishi M et al (2001) Tumour amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824–831PubMedCrossRef
19.
Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez G et al (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320–1329PubMedCrossRef
20.
Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92:370–373PubMedCrossRef
21.
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M et al (2003) Activation and overexpression of centrosome kinase BTAK/Aurora- A in human ovarian cancer. Clin Cancer Res 9:1420–1426PubMed
22.
Chung CM, Man C, Jin Y, Guan XY, Wang Q et al (2005) Amplification and overexpression of aurora kinaseA (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 43:165–174PubMedCrossRef
23.
Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T et al (2005) The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 11:1827–1834PubMedCrossRef
24.
Tong T, Zhong Y, Kong J, Dong L, Song Y et al (2004) Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10:7304–7310PubMedCrossRef
25.
Reiter R, Gais P, Jütting U, Steuer-Vogt MK, Pickhard A et al (2006) Aurora kinase A messenger RNA overexpression is correlated with tumour progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 12:5136–5141PubMedCrossRef
26.
Ruan Y, Song AP, Wang H, Xie YT, Han JY et al (2011) Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population. J Pathol 225:535–543PubMedCrossRef
27.
Sun H, Bai J, Chen F, Jin Y, Yu Y et al (2011) Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects. Breast Cancer Res Treat 125:175–179PubMedCrossRef
28.
Liu L, Yuan P, Wu C, Zhang X, Wang F et al (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73:110–115PubMedCrossRef
29.
Wei S-Z, Zhan P, Shi M, Qian Q, Yu L, Song Y (2011) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 28:315–321PubMedCrossRef
30.
Yin M, Yan J, Voutsina J, Tibaldi C, Christiani DC et al (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 73:370–377CrossRef
31.
Wei HB, Hu J, Shang LH, Zhang YY, Lu FF et al (2012) A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J 125:2902–2907PubMed
32.
Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7:e38150PubMedCrossRef
33.
Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S et al (2007) Prospective assessment of XPD Lys751Gln and XDCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13:2876–2881PubMedCrossRef
34.
Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F et al (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41:81–92PubMedCrossRef
35.
Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 1:2937–2945CrossRef
36.
Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F et al (2008) Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 61:369–377PubMedCrossRef
37.
Provencio M, Blanco R, Alberola V, Isla D, Massuti B et al. (2007) Cisplatin plus vinorelbine as first-line treatment for patients with advanced non-small cell lung cancer: molecular correlates. In: 14th European cancer conference, ECCO 14, Barcelona, pp 23–27. September, 2007
38.
Yang H, He L, Kruk P, Nicosia SV, Cheng JQ (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119:2304–2312PubMedCrossRef
39.
Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51–62PubMedCrossRef
40.
Pan JY, Ajani JA, Gu J, Gong Y, Quin A et al (2012) Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 118:4346–4353PubMedCrossRef
41.
Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V et al (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71:191–198PubMedCrossRef
Metadata
Title
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer
Authors
M. Provencio
C. Camps
M. Cobo
R. De las Peñas
B. Massuti
R. Blanco
V. Alberola
U. Jimenez
J. R. Delgado
F. Cardenal
M. Tarón
J. L. Ramírez
A. Sanchez
R. Rosell
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-1985-9

Other articles of this Issue 6/2012

Cancer Chemotherapy and Pharmacology 6/2012 Go to the issue

Original Article

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Original Article

6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation

Original Article

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy

Original Article

Phase I study of nelfinavir in liposarcoma

Original Article

Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro

Original Article

Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits